Island Pharmaceuticals Begins Strategic Collaboration With Australian Infectious Disease Research Organization

MT Newswires Live
03/09

Island Pharmaceuticals (ASX:ILA) began a strategic research collaboration with Burnet Institute in Australia to evaluate the potential application of Island's drug candidates, ISLA-101 and Galidesivir, against targets including measles, chikungunya, and Ross River viruses, according to a Monday Australian bourse filing.

Burnet will assess in vitro and translational studies of the antiviral activity of ISLA-101 and Galidesivir against selected viral pathogens.

Its shares rose 1% in recent trading on Monday.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10